Using high doses of Novo Nordisk's anti-clotting medicine to treat dangerous bleeding in non-haemophiliacs may raise the risk of heart attack or related complications, researchers said.
The drug, NovoSeven, is a genetically engineered version of factor VII, a key protein missing in some people with the bleeding disease haemophilia.
via tvnz.co.nz
No comments:
Post a Comment